New York State Common Retirement Fund Raises Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

New York State Common Retirement Fund boosted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 155,426 shares of the company's stock after purchasing an additional 7,735 shares during the period. New York State Common Retirement Fund owned approximately 0.17% of Crinetics Pharmaceuticals worth $7,947,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in CRNX. Barclays PLC boosted its holdings in shares of Crinetics Pharmaceuticals by 75.5% during the third quarter. Barclays PLC now owns 207,712 shares of the company's stock worth $10,614,000 after purchasing an additional 89,358 shares during the period. Franklin Resources Inc. raised its position in shares of Crinetics Pharmaceuticals by 61.4% during the third quarter. Franklin Resources Inc. now owns 1,390,110 shares of the company's stock valued at $73,815,000 after buying an additional 528,688 shares during the last quarter. Geode Capital Management LLC increased its holdings in Crinetics Pharmaceuticals by 10.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company's stock valued at $94,458,000 after buying an additional 169,746 shares during the period. SG Americas Securities LLC lifted its position in shares of Crinetics Pharmaceuticals by 4,084.6% during the 4th quarter. SG Americas Securities LLC now owns 542,446 shares of the company's stock worth $27,735,000 after buying an additional 529,483 shares during the period. Finally, Jennison Associates LLC grew its stake in Crinetics Pharmaceuticals by 0.5% during the third quarter. Jennison Associates LLC now owns 2,793,614 shares of the company's stock worth $142,754,000 after buying an additional 13,470 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company's stock.

Remove Ads

Crinetics Pharmaceuticals Stock Up 7.7 %

Crinetics Pharmaceuticals stock traded up $2.57 during trading on Friday, hitting $35.78. The stock had a trading volume of 2,042,034 shares, compared to its average volume of 1,034,224. The stock's 50 day moving average is $41.17 and its two-hundred day moving average is $50.07. Crinetics Pharmaceuticals, Inc. has a 1 year low of $31.84 and a 1 year high of $62.53. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of -9.59 and a beta of 0.56.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Dana Pizzuti sold 5,000 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total value of $195,350.00. Following the completion of the sale, the insider now owns 31,748 shares of the company's stock, valued at approximately $1,240,394.36. This represents a 13.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRNX shares. TD Cowen assumed coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating for the company. Jefferies Financial Group raised shares of Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a research report on Wednesday, January 22nd. Wolfe Research assumed coverage on Crinetics Pharmaceuticals in a report on Tuesday, February 4th. They set a "peer perform" rating for the company. Citigroup boosted their target price on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a "buy" rating in a research report on Thursday, November 14th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $87.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $72.64.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.